Cystic Fibrosis New Zealand has a mission to work towards a better quality of life for all people with cystic fibrosis, through research into better treatment and management of the condition.
We are working in collaboration with Cure Kids to fund quality of life and quality of improvement studies. CFNZ welcomes inquiries from scientists and clinicians who are seeking support for their research initiatives.
We own the PORT CF data registry which holds anonymous data related to the health and genetics of the CF population in New Zealand, and researchers are able to access this non-identifiable data to support their research activities.
Internationally, much progress is being made to correct the underlying cause of cystic fibrosis and improve mucus clearance. The Cystic Fibrosis Foundation’s website includes a drug development pipeline with the latest stages of new therapies being trialled.Email the Chief Executive about PORT CF or research funding
Gene therapy, which aims to repair CF cells in the lungs, is another treatment that looks promising for the future.
A new gene-editing technique (known as CRISPR) to repair the cystic fibrosis gene is being studied at a number of research institutes overseas. However, this research is still in the very early stages.Find out more
CFNZ and Cure Kids are jointly funding two research projects – one for a new device for chest therapy for children and the other to target the bacteria Pseudomonas aeruginosa (P. aeruginosa) which causes a serious lung infection in people with CF.
Associate Professor Cass Byrnes of University of Auckland & Starship Children’s Hospital is a leader in clinical care of children with CF throughout NZ. Her research focuses on the prevention of respiratory disease in children with cystic fibrosis or post pneumonia bronchiectasis. She is the NZ principle investigator for a number of international trials in CF (ACFBAL trial, COMBAT CF trial, GAIN, FAB) and most recently received a grant from CFNZ and Cure Kids to explore making physiotherapy a game – rather than the daily chore it becomes for children with CF.
The tablet-based game, BreatheHero, rewards kids when they perform physiotherapy correctly, as well as collecting data on how often the exercises are performed. It is hoped that the more engaging form of therapy will see an uplift in compliance levels among children and adolescents, which currently sits at around 49%.
The BreatheHero™ research team is co-led by Associate Professor Cass Byrnes, Dr Christof Lutteroth from the Department of Computer Science at the University of Auckland and Hamed Minaei based in the Auckland Bioengineering Institute, and includes engineering expert Dr Robert Gallichan and business consultant Dr Katherine Lutteroth.
While final results of the research will not be available until later this year, anecdotal feedback from families has reported a significant improvement in both compliance and adherence to the vital therapy.
The team has been guided in technical design by Marcus King at Callaghan Innovation who has extensive experience developing medical devices, including the AbleX device for stroke rehabilitation.
A second research project to study the common bacteria, Pseudomonas aeruginosa, which is public enemy number one for CF patients, is being led by Professor Iain Lamont Director of the Genetics Teaching Programme at Department of Biochemistry at Otago University who has a long-standing interest in understanding how bacteria cause infectious disease.
He and his research team are using a range of tools to understand how P. aeruginosa survives and resists antibiotics during infection, with the long-term aim of developing new treatments. Antibiotics kill P. aeruginosa in the research lab but once established in the lungs, they are no defence against the P. aeruginosa. It is thought that this is partly due to how the bacteria grows in the lab versus the reality of the environment in the lungs.
When present in the lungs, P. aeruginosa is under an oxygen-starved environment. This is at odds with P. aeruginosa grown in a lab, which is usually under conditions replete with oxygen. It is these oxygen-rich lab conditions where antibiotics are tested and hence may not reflect the reality of the lung environment.
It is suspected that the bacteria respond to the deficiency in oxygen by triggering 'oxygen starvation' genes to fight the effects of the antibiotics.
Prof Iain Lamont is investigating these genetic changes by exposing the bacteria to different levels of oxygen in the lab. The insight gained from this research could lead to more targeted antibiotic treatments for P. aeruginosa.
CFNZ has previously provided grants for the following important research initiatives:
Cystic Fibrosis New Zealand moderates Cystic Fibrosis Research News, a Facebook page for people interested in being kept informed about new treatments in the pipeline. This page is an open group for people with an interest in cystic fibrosis research, both local and global, to post anything new for others to read and share.
There are also a number of research journals and resources that report on cystic fibrosis:
Donate to global CF research